Associations of metabolic heterogeneity of obesity with the risk of dementia in middle-aged adults: three prospective studies.

IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY
Yihong Ding, Tian Ge, Jie Shen, Mingrui Duan, Changzheng Yuan, Yimin Zhu, Dan Zhou
{"title":"Associations of metabolic heterogeneity of obesity with the risk of dementia in middle-aged adults: three prospective studies.","authors":"Yihong Ding, Tian Ge, Jie Shen, Mingrui Duan, Changzheng Yuan, Yimin Zhu, Dan Zhou","doi":"10.1186/s13195-024-01581-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The associations of different obesity and metabolic phenotypes during midlife with the risk of incident dementia remain unclear. This study aimed to investigate the associations between metabolic heterogeneity of obesity and long-term risk of dementia.</p><p><strong>Methods: </strong>We conducted prospective analyses from three cohorts, including the UK Biobank (UKB), Atherosclerosis Risk in Communities (ARIC) study, and Framingham Offspring Study (FOS). Eligible participants were those aged 45-65 years with valid assessments of body mass index (BMI) and metabolic status at the study baseline. Obesity was defined as a BMI of ≥ 30.0 kg/m<sup>2</sup>, while metabolic abnormality was defined as meeting ≥ 2 of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria. Metabolic heterogeneity of obesity was evaluated based on obesity and metabolic phenotypes and grouped as metabolically normal non-obesity (MNNO), metabolically abnormal non-obesity (MANO), metabolically normal obesity (MNO), and metabolically abnormal obesity (MAO).</p><p><strong>Results: </strong>Included in this study were 295,823 participants aged 56.3 ± 5.9 years from the UKB, 12,547 participants aged 54.0 ± 5.7 years from the ARIC, and 2,004 participants aged 53.9 ± 5.9 years from the FOS. Over 4,348,208 person-years, a total of 6,190 participants (3,601 in the UKB, 2,405 in the ARIC, and 184 in the FOS) developed incident dementia. In the pooled analysis of three cohorts, metabolic abnormality was associated with a hazard ratio (HR) of 1.41 (95% confidence interval [CI]: 1.10-1.80) for dementia, while obesity was associated with an HR of 1.20 (1.03-1.41). Compared with MNNO, individuals with MANO and MAO had increased risks of dementia (pooled HR: 1.33, 95% CI: 1.04-1.71 for MANO and 1.48, 1.16-1.89 for MAO). However, there was no significant difference in the risk of dementia among MNO (pooled HR: 1.10, 95% CI: 0.98-1.24). In addition, participants who recovered from MANO to MNNO had a lower risk of dementia (pooled HR: 0.79, 95% CI: 0.64-0.97), as compared with stable MANO.</p><p><strong>Conclusions: </strong>Metabolic abnormality has a stronger association with dementia than obesity. Metabolically abnormal non-obesity and obesity, but not metabolically normal obesity, are associated with higher risks of incident dementia as compared with metabolically normal non-obesity. Recovering from an abnormal metabolic status to normal reduces the risk of dementia in populations without obesity. Our findings highlight the important role of metabolic status in the development of dementia and recommend the stratified management of obesity based on metabolic status.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"220"},"PeriodicalIF":7.9000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-024-01581-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The associations of different obesity and metabolic phenotypes during midlife with the risk of incident dementia remain unclear. This study aimed to investigate the associations between metabolic heterogeneity of obesity and long-term risk of dementia.

Methods: We conducted prospective analyses from three cohorts, including the UK Biobank (UKB), Atherosclerosis Risk in Communities (ARIC) study, and Framingham Offspring Study (FOS). Eligible participants were those aged 45-65 years with valid assessments of body mass index (BMI) and metabolic status at the study baseline. Obesity was defined as a BMI of ≥ 30.0 kg/m2, while metabolic abnormality was defined as meeting ≥ 2 of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria. Metabolic heterogeneity of obesity was evaluated based on obesity and metabolic phenotypes and grouped as metabolically normal non-obesity (MNNO), metabolically abnormal non-obesity (MANO), metabolically normal obesity (MNO), and metabolically abnormal obesity (MAO).

Results: Included in this study were 295,823 participants aged 56.3 ± 5.9 years from the UKB, 12,547 participants aged 54.0 ± 5.7 years from the ARIC, and 2,004 participants aged 53.9 ± 5.9 years from the FOS. Over 4,348,208 person-years, a total of 6,190 participants (3,601 in the UKB, 2,405 in the ARIC, and 184 in the FOS) developed incident dementia. In the pooled analysis of three cohorts, metabolic abnormality was associated with a hazard ratio (HR) of 1.41 (95% confidence interval [CI]: 1.10-1.80) for dementia, while obesity was associated with an HR of 1.20 (1.03-1.41). Compared with MNNO, individuals with MANO and MAO had increased risks of dementia (pooled HR: 1.33, 95% CI: 1.04-1.71 for MANO and 1.48, 1.16-1.89 for MAO). However, there was no significant difference in the risk of dementia among MNO (pooled HR: 1.10, 95% CI: 0.98-1.24). In addition, participants who recovered from MANO to MNNO had a lower risk of dementia (pooled HR: 0.79, 95% CI: 0.64-0.97), as compared with stable MANO.

Conclusions: Metabolic abnormality has a stronger association with dementia than obesity. Metabolically abnormal non-obesity and obesity, but not metabolically normal obesity, are associated with higher risks of incident dementia as compared with metabolically normal non-obesity. Recovering from an abnormal metabolic status to normal reduces the risk of dementia in populations without obesity. Our findings highlight the important role of metabolic status in the development of dementia and recommend the stratified management of obesity based on metabolic status.

肥胖代谢异质性与中年人痴呆症风险的关系:三项前瞻性研究。
背景:中年时期不同肥胖和代谢表型与痴呆症发病风险的关系仍不清楚。本研究旨在调查肥胖的代谢异质性与痴呆症长期风险之间的关系:我们对英国生物库(UKB)、社区动脉粥样硬化风险(ARIC)研究和弗雷明汉后代研究(FOS)等三个队列进行了前瞻性分析。符合条件的参与者年龄在 45-65 岁之间,在研究基线时对体重指数 (BMI) 和代谢状况进行了有效评估。肥胖的定义是体重指数≥ 30.0 kg/m2,而代谢异常的定义是符合美国国家胆固醇教育计划-成人治疗小组 III(NCEP-ATP III)标准中的≥ 2 项标准。根据肥胖和代谢表型评估肥胖的代谢异质性,并将其分为代谢正常非肥胖(MNNO)、代谢异常非肥胖(MANO)、代谢正常肥胖(MNO)和代谢异常肥胖(MAO):这项研究包括英国肥胖调查(UKB)中 295,823 名年龄在 56.3 ± 5.9 岁之间的参与者,ARIC 中 12,547 名年龄在 54.0 ± 5.7 岁之间的参与者,以及 FOS 中 2,004 名年龄在 53.9 ± 5.9 岁之间的参与者。在 4,348,208 人年中,共有 6,190 名参与者(其中 3,601 人来自 UKB,2,405 人来自 ARIC,184 人来自 FOS)罹患痴呆症。在对三个队列的汇总分析中,代谢异常与痴呆症的危险比 (HR) 为 1.41(95% 置信区间 [CI]:1.10-1.80),而肥胖与痴呆症的危险比为 1.20(1.03-1.41)。与MNNO相比,MANO和MAO患者患痴呆症的风险增加(汇总HR:MANO为1.33,95% CI:1.04-1.71;MAO为1.48,1.16-1.89)。然而,MNO患者患痴呆症的风险没有明显差异(汇总HR:1.10,95% CI:0.98-1.24)。此外,与稳定的MANO相比,从MANO恢复到MNNO的参与者患痴呆症的风险较低(汇总HR:0.79,95% CI:0.64-0.97):结论:代谢异常与痴呆的关系比肥胖更密切。与代谢正常的非肥胖症患者相比,代谢异常的非肥胖症患者和肥胖症患者(代谢正常的肥胖症患者除外)患痴呆症的风险更高。在没有肥胖症的人群中,从代谢异常状态恢复到正常状态会降低患痴呆症的风险。我们的研究结果强调了代谢状态在痴呆症发病中的重要作用,并建议根据代谢状态对肥胖症进行分层管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信